{"name":"BioAxone BioSciences, Inc.","slug":"bioaxone-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPNWw2SC1fc2EzUnlmeGotaWJ2MkNfempIZllBc1l6RmUtMWFNZjdRS2praVFDZnFPSnhMS09OQ0JvNUtDVUNUZWs5MlFWUk1aeVRkZVY1ZG9wM1VsWEt6THpPMEFYdGdIakpzUjRxSlV5b3lsc3BTLU8xbHAwajNLOWRRRi1VWVlKelMyVWFMb205clU?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Segmentation, Major Trends, and Competitive Overview of the Acute Spinal Cord Injury Market - openPR.com","headline":"Segmentation, Major Trends, and Competitive Overview of the Acute Spinal Cord Injury Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1ySW0yVUVzcG9xeDIxbUhlY3l0UXUtZ29qc3FIdHN4RjJDME9DOFZOaC16dDlMX0ozWDdqTENjUE1EZTZ0cmV3OVJ4aTB4Y0ZQb2hsWjktSUFuWHdPUjJz?oc=5","date":"2020-09-02","type":"pipeline","source":"nature.com","summary":"Transforming treatments for neurotrauma and neurovascular disorders - nature.com","headline":"Transforming treatments for neurotrauma and neurovascular disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPcVNLRHIwendjRW9nNE5tajJnZWxiSC1vV0h2ZFRVNXRzYTRZdFBIOWdaZ3lfTVJFek04RlBUMHpHSmRMUnE1Z1JIQV85N2l6RUFWMFJOQWhfd0JBQlROdU01aVhJbUVWN0xzY1pZQW5KZzR0VVpGUFNzZEg2bkYwY3NOX0JfVWtUazJR?oc=5","date":"2017-01-10","type":"pipeline","source":"massbio.org","summary":"An Open Letter to the BioPharma Community - massbio.org","headline":"An Open Letter to the BioPharma Community","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}